MYRIAD GENETICS, INC.

Five institutional shareholders are disclosed for Myriad Genetics, Inc. in the registry data underlying this profile, drawn from SEC-reportable institutional holdings (Schedule 13F/13G) rather than a complete shareholder register, which is not published for Nasdaq-listed companies with dispersed public ownership. As of the most recent snapshot reflected in these filings (4 September 2026), the largest disclosed holder is Vanguard Group Inc, reporting 8,225,371 shares (approximately 11.6 percent). This figure matches the 8,225,371-share position that Vanguard Group Inc was independently reported to hold in its own SEC disclosure, corroborating the registry data for this holder. The other disclosed holders are iShares Trust – iShares Core S&P Small-Cap ETF (approximately 7.9 percent), iShares Trust – iShares Russell 2000 ETF (approximately 3.2 percent), Fidelity Salem Street Trust – Fidelity Small Cap Index Fund (approximately 1.3 percent), and iShares Trust – iShares Russell 2000 Value ETF (approximately 1.1 percent). All five disclosed holders are passive index or institutional funds rather than individuals. A separate Schedule 13G/A filed with the SEC shows BlackRock, Inc. also held a major position of 7,976,163 shares (approximately 8.5 percent) as of 31 March 2026, a holding not captured in the registry snapshot above, confirming that the disclosed list reflects major shareholders only rather than the company’s complete shareholder base.

Data availability

Shareholder information for Myriad Genetics, Inc. is classified as major shareholders only: as a Nasdaq-listed public company, it discloses beneficial ownership only for holders that cross SEC reporting thresholds or that file Schedule 13F institutional holdings reports, not its full shareholder base. No verified ultimate beneficial owner is identified, because every disclosed shareholder is an institutional investment fund rather than a natural person, and a complete ownership chain to an individual cannot be established from these filings.

Sources

• Myriad Genetics, Inc. registry shareholder data (institutional holdings, Schedule 13F/13G basis); retrieval date 4 September 2026.
• U.S. Securities and Exchange Commission, EDGAR filings index for Myriad Genetics, Inc. (CIK 0000899923), Schedule 13G/13G-A filings – sec.gov; includes Vanguard Group Inc and BlackRock, Inc. disclosures; retrieved 11 September 2026.

Myriad Genetics, Inc. discloses its directors and executive officers through SEC filings and investor communications rather than through a state company register. As of its current corporate governance disclosures, the Board of Directors comprises eight members: S. Louise Phanstiel (Chair of the Board, a director since September 2009), President and Chief Executive Officer Sam Raha, and non-employee directors Paul M. Bisaro, Mark S. Davis, Heiner Dreismann, Rashmi Kumar, Lee N. Newcomer, and Colleen F. Reitan. Named executive officers include Sam Raha (President and Chief Executive Officer, since 30 April 2025), R. Bryan Riggsbee (Executive Vice President, Chief Financial Officer and Treasurer, in the role since October 2014), and Mark S. Verratti (Chief Operating Officer, since 30 April 2025). No officer or director covered here is recorded as resigned or removed in the sources reviewed; all are current appointments. Nationality and country of residence are not disclosed for any officer or director in these sources.

Recent officer changes

• Paul J. Diaz stepped down as President and Chief Executive Officer, and Sam Raha, previously Chief Operating Officer, was appointed President, Chief Executive Officer and a director, both effective 30 April 2025 (source: Myriad Genetics, Inc. Form 8-K, U.S. Securities and Exchange Commission).
• Mark S. Verratti, previously Chief Commercial Officer, was promoted to Chief Operating Officer effective 30 April 2025, concurrent with Mr. Raha’s appointment (source: same Form 8-K).
• Mark S. Davis was elected to the Board of Directors effective 10 December 2024 (source: Myriad Genetics, Inc. press release, GlobeNewswire, 10 December 2024).

Data availability

Officer and director information for Myriad Genetics, Inc. is fully public, since the company is subject to SEC proxy and disclosure rules and publishes current governance details through its investor relations site and periodic filings. This overview is based on those sources rather than the officer records shown elsewhere in this profile, which include role titles – for example, more than one individual recorded as holding the board chair title – that could not be corroborated against the company’s current SEC filings or investor relations disclosures and have therefore not been relied upon here.

Sources

• Myriad Genetics, Inc., Corporate Governance – investor.myriad.com/corporate-governance; retrieved 11 September 2026.
• Myriad Genetics, Inc., Form 8-K (leadership transition), U.S. Securities and Exchange Commission – sec.gov; effective 30 April 2025, retrieved 11 September 2026.
• Myriad Genetics, Inc., “Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member,” GlobeNewswire – globenewswire.com; published 10 December 2024, retrieved 11 September 2026.

Myriad Genetics, Inc. is a publicly traded Delaware corporation. No parent company or controlling shareholder is identified in its SEC filings; the company is itself the top entity in its corporate group. Its List of Subsidiaries of the Registrant (Exhibit 21.1), filed with its Form 10-K for the year ended 31 December 2025, identifies eight wholly-owned subsidiaries: four incorporated in Delaware, United States (Myriad Genetic Laboratories, Inc.; Assurex Health, Inc.; Gateway Genomics, LLC; and Myriad Women’s Health, Inc.) and four incorporated outside the United States (Myriad GmbH in Germany, Myriad Genetics GmbH in Switzerland, Myriad Genetics B.V. in the Netherlands, and Myriad Genetics GK in Japan). This differs from the parent-subsidiary linkage shown elsewhere in this profile, which lists Myriad Genetics GmbH as sitting above Myriad Genetics, Inc. in the ownership chain – the reverse of the relationship confirmed in the company’s own SEC exhibit. That linkage could not be corroborated against SEC filings and has not been relied upon in this section.

Verified corporate relationships

Swipe or scroll for more columns

The Exhibit 21.1 filing describes each of these entities as a wholly-owned subsidiary of Myriad Genetics, Inc. but does not specify whether this reflects share capital, voting rights, or another basis of control, and it does not disclose registration numbers.

Data availability

Corporate-linkage information for Myriad Genetics, Inc. is full at the parent level (no parent identified, consistent with its status as a publicly traded company) and partial at the subsidiary level: subsidiary names and jurisdictions are disclosed, but registration numbers and the precise ownership basis are not itemised in the source exhibit.

Sources

• Myriad Genetics, Inc., Form 10-K for the fiscal year ended 31 December 2025, Exhibit 21.1 “List of Subsidiaries of the Registrant,” U.S. Securities and Exchange Commission – sec.gov; filed February 2026, retrieved 11 September 2026.